600479 千金药业
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,000,7414.22%3,798,4854,026,2793,663,8453,626,967
减:营业总成本921,1133.11%3,356,2173,614,6553,302,0193,254,437
    其中:营业成本543,0001.53%2,046,7292,289,8652,032,2382,030,778
               财务费用(1,307)-207.99%(45,430)(3,330)(6,118)(27,451)
               资产减值损失----(2,571)(1,270)(1,403)(3,474)
公允价值变动收益990-177.55%(1,597)(1,297)4,7202,082
投资收益(2,725)-157.76%17,46920,94721,69122,085
    其中:对联营企业和合营企业的投资收益(2,725)77.44%8,024(3,640)3350
营业利润71,2857.91%461,940444,247436,232424,179
利润总额71,5258.29%460,419445,813433,422424,585
减:所得税费用10,51713.03%65,40358,66758,68264,378
净利润61,0087.51%395,017387,146374,740360,207
减:非控股权益14,81015.33%74,61184,63772,67663,136
股东净利润46,1985.22%320,406302,509302,063297,072

市场价值指针
每股收益 (元) *0.1085.48%0.7580.7070.7220.710
每股派息 (元) *----0.3500.3500.6001.000
每股净资产 (元) *5.6837.90%5.5715.1565.1385.416
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容